Modality
Vaccine
MOA
JAK1i
Target
C5
Pathway
Ferroptosis
RSV
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
~Jun 2019
→ ~Sep 2020
Phase 2
Dec 2020
→ Oct 2026
Phase 2Current
NCT04531042
204 pts·RSV
2023-03→2026-10·Recruiting
NCT07065589
556 pts·RSV
2020-12→2026-03·Recruiting
760 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-182w agoPh2 Data· RSV
2026-10-177mo awayPh2 Data· RSV
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2026-03-18 · 2w ago
RSV
Ph2 Data
2026-10-17 · 7mo away
RSV
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04531042 | Phase 2 | RSV | Recruiting | 204 | PASI75 |
| NCT07065589 | Phase 2 | RSV | Recruiting | 556 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ARG-1250 | Argenx | Phase 2 | C5 |